Single-Center, Open-Label Study Study to Evaluate Improvement of Hair Appearance With Novel Hair Growth Serum.

IF 1.5 4区 医学 Q3 DERMATOLOGY
Suleima Arruda, Alyssa Swearingen, Zahyaa Elmadany, Anna Nakagama, Emely Alvarado Lemoine, Sophia Clara Valmeus, Neil Sadick
{"title":"Single-Center, Open-Label Study Study to Evaluate Improvement of Hair Appearance With Novel Hair Growth Serum.","authors":"Suleima Arruda, Alyssa Swearingen, Zahyaa Elmadany, Anna Nakagama, Emely Alvarado Lemoine, Sophia Clara Valmeus, Neil Sadick","doi":"10.36849/JDD.8606","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>REVIVV&reg; is a topical hair growth serum with a proprietary formula of botanicals that addresses multiple factors involved in hair loss pathophysiology. This open-label, prospective, single-center study evaluated the efficacy of REVIVV&reg;, a topical hair growth serum, in 20 adults (10 male, 10 female) with mild to moderate hair loss over 6 months. Participants applied the serum twice daily, and assessments were conducted at baseline, 4, 12, and 24 weeks. Dermatologist evaluations and patient self-assessments of hair quality and growth were performed using a 7-point Likert scale. Results Investigator-rated improvements in hair quality and growth increased from 0.75 and 0.81 at 4 weeks to 1.73 and 1.83 at 24 weeks, respectively. Patient-reported assessments showed that 85% of participants noted improved hair quality and growth at 24 weeks, with 50% reporting great improvement. Patient satisfaction was high, with 80% of participants being moderately or greatly satisfied at 4 weeks, increasing to 95% at 24 weeks. No adverse events related to the serum were reported throughout the study. The results demonstrate that twice-daily application of REVIVV&reg; &nbsp;over 6 months is associated with increased hair growth and improved hair quality suggesting that REVIVV&reg; &nbsp;may be an effective, non-pharmacological option for individuals seeking to improve hair growth and quality. J Drugs Dermatol. 2025;24(4):394-396. doi:10.36849/JDD.8606&nbsp.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"394-396"},"PeriodicalIF":1.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.8606","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: REVIVV® is a topical hair growth serum with a proprietary formula of botanicals that addresses multiple factors involved in hair loss pathophysiology. This open-label, prospective, single-center study evaluated the efficacy of REVIVV®, a topical hair growth serum, in 20 adults (10 male, 10 female) with mild to moderate hair loss over 6 months. Participants applied the serum twice daily, and assessments were conducted at baseline, 4, 12, and 24 weeks. Dermatologist evaluations and patient self-assessments of hair quality and growth were performed using a 7-point Likert scale. Results Investigator-rated improvements in hair quality and growth increased from 0.75 and 0.81 at 4 weeks to 1.73 and 1.83 at 24 weeks, respectively. Patient-reported assessments showed that 85% of participants noted improved hair quality and growth at 24 weeks, with 50% reporting great improvement. Patient satisfaction was high, with 80% of participants being moderately or greatly satisfied at 4 weeks, increasing to 95% at 24 weeks. No adverse events related to the serum were reported throughout the study. The results demonstrate that twice-daily application of REVIVV®  over 6 months is associated with increased hair growth and improved hair quality suggesting that REVIVV®  may be an effective, non-pharmacological option for individuals seeking to improve hair growth and quality. J Drugs Dermatol. 2025;24(4):394-396. doi:10.36849/JDD.8606 .

单中心、开放标签研究:评价新型毛发生长血清对头发外观改善的研究。
背景:REVIVV®是一种局部头发生长血清与专利配方的植物,解决涉及脱发病理生理的多种因素。这项开放标签、前瞻性、单中心研究评估了revvv®(一种局部毛发生长血清)在20名轻度至中度脱发超过6个月的成年人(10名男性,10名女性)中的疗效。参与者每天使用血清两次,并在基线、4周、12周和24周进行评估。皮肤科医生评估和患者自我评估头发质量和生长使用7分李克特量表进行。结果研究人员评定的头发质量和生长的改善分别从4周时的0.75和0.81增加到24周时的1.73和1.83。患者报告的评估显示,85%的参与者在24周时表示头发质量和生长有所改善,50%的人表示有很大改善。患者满意度很高,80%的参与者在4周时感到中等或非常满意,在24周时增加到95%。在整个研究过程中未报告与血清相关的不良事件。结果表明,每天两次的REVIVV®;超过6个月与头发生长增加和头发质量改善有关,这表明reviv ®;对于寻求改善头发生长和质量的个人来说,可能是一种有效的、非药物的选择。皮肤医学杂志,2025;24(4):394-396。doi: 10.36849 / JDD.8606 。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.20
自引率
13.30%
发文量
289
审稿时长
3-6 weeks
期刊介绍: The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology. We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality. Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信